newsfilter
← Earnings
Earnings Releases·

Cabaletta Bio — Third Quarter 2026 Earnings Summary

  • Net loss widened to $53.1 million ($0.28 per share) for Q3 2026 from $44.9 million ($0.44 per share) in Q3 2025, driven by a 17% increase in total operating expenses to $54.7 million.
  • Cash position strengthened to $299.4 million as of September 30, 2026, including $115.0 million from warrant exercises, extending the operational runway into Q1 2028.
  • Registrational topline results for the RESET-Myositis adult cohort are anticipated in H2 2027, supporting a BLA submission in Q1 2028 that will include juvenile dermatomyositis data for a potential Priority Review Voucher.
  • The registrational RESET-SSc cohort for systemic sclerosis with interstitial lung disease has initiated enrollment, while the Phase 1/2 juvenile myositis program is open with an outpatient dosing option.
  • Enrollment activity in the adult myositis study has increased following a slower Q3 2026 period, with management highlighting a favorable benefit-risk profile and plans to present one-year durability data at ACR Convergence 2026.
Company
CABALETTA BIO INC
Sector
Healthcare
Industry
Biotechnology